Journal article

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Arwen F Altenburg, Carolien E van de Sandt, Bobby WS Li, Ronan J MacLoughlin, Ron AM Fouchier, Geert van Amerongen, Asisa Volz, Rudi W Hendriks, Rik L de Swart, Gerd Sutter, Guus F Rimmelzwaan, Rory D de Vries

Scientific Reports | NATURE PUBLISHING GROUP | Published : 2017

Abstract

Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vitro, ex vivo and in vivo experiments with recombinant MVA expressing green fluorescent protein (rMVA-GFP). In both human peripheral blood mononuclear cells and mouse lung explants, rMVA-GFP predominantly infected antigen presenting cells. Subsequent in vivo experiments performed in mice, ferrets and non-human primates indicated that preferential targeting of dendritic cells and alveolar macrophages was obse..

View full abstract

Grants

Awarded by European Commission FP7 project FLUNIVAC


Awarded by European Research Council grant FLUPLAN


Funding Acknowledgements

The authors would like to thank Mark Pronk, Nella Nieuwkoop, Stella van Trierum, Heidi De Gruyter, Alwin de Jong and Peter van Run for excellent technical assistance. This project was funded by the European Commission FP7 project FLUNIVAC (project number 602604) and the European Research Council grant FLUPLAN (250136).